{
    "clinical_study": {
        "@rank": "33376", 
        "arm_group": [
            {
                "arm_group_label": "GS-5806", 
                "arm_group_type": "Experimental", 
                "description": "Single dose, oral liquid, .5 mL/kg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single dose, oral liquid, .5 mL/kg"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of\n      GS-5806 in hospitalized infants with RSV."
        }, 
        "brief_title": "Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Respiratory Syncytial Virus Infections", 
        "condition_browse": {
            "mesh_term": [
                "Respiratory Syncytial Virus Infections", 
                "Respiratory Tract Infections", 
                "Virus Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  <24 months of age\n\n          -  Diagnosis of Respiratory Syncytial Virus (RSV) within 48 hours of screening\n\n        Exclusion Criteria:\n\n          -  Chronic or congenital heart disease\n\n          -  Required ventilation or admission to any pediatric Intensive Care Unit\n\n          -  Inadequate organ function"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "24 Months", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01797419", 
            "org_study_id": "GS-US-218-0104"
        }, 
        "intervention": [
            {
                "arm_group_label": "GS-5806", 
                "description": "Single dose, oral liquid, .5 mL/kg", 
                "intervention_name": "GS-5806", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Single dose, oral liquid, .5 mL/kg", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Respiratory", 
            "Syncytial", 
            "Virus", 
            "RSV"
        ], 
        "lastchanged_date": "October 24, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Geelong", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3220"
                    }, 
                    "name": "Geelong Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clayton", 
                        "country": "Australia"
                    }, 
                    "name": "Monash Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Herston", 
                        "country": "Australia"
                    }, 
                    "name": "Queensland Children's Medical Research Unit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hobart", 
                        "country": "Australia"
                    }, 
                    "name": "Royal Hobart Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "North Adelaide", 
                        "country": "Australia"
                    }, 
                    "name": "Women's and Children's Hospital Adelaide"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Parkville", 
                        "country": "Australia"
                    }, 
                    "name": "Royal Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Randwick", 
                        "country": "Australia"
                    }, 
                    "name": "Sydney Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Subiaco", 
                        "country": "Australia"
                    }, 
                    "name": "Princess Margaret Hospital for Children"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Westmead", 
                        "country": "Australia"
                    }, 
                    "name": "Westmead Children's Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Ranging Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5806 in Subjects < 24 Months of Age Hospitalized for Respiratory Syncytial Virus (RSV) Related Respiratory Infection", 
        "overall_official": {
            "affiliation": "Queensland Children's Medical Research Unit, Herston, AUS", 
            "last_name": "Peter Sly, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety and tolerability will be assessed by evaluating AE's, laboratory abnormalities and vital sign measurements.", 
            "measure": "Safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "10 days from subject randomization to study drug"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01797419"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Evaluation of GS-5806 on viral load related and symptom related endpoints.", 
            "measure": "Pharmacokinetics effects of GS-5806", 
            "safety_issue": "No", 
            "time_frame": "10 days from subject randomization to study drug"
        }, 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}